Advertisement
Canada markets open in 3 hours 13 minutes

  • S&P/TSX

    21,871.96
    +64.59 (+0.30%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CAD/USD

    0.7297
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    81.97
    +0.07 (+0.09%)
     

  • Bitcoin CAD

    90,672.61
    +154.90 (+0.17%)
     

  • CMC Crypto 200

    1,420.03
    +5.27 (+0.37%)
     

  • GOLD FUTURES

    2,312.90
    -33.50 (-1.43%)
     

  • RUSSELL 2000

    1,967.47
    +19.82 (+1.02%)
     

  • 10-Yr Bond

    4.6230
    +0.0080 (+0.17%)
     

  • NASDAQ futures

    17,372.50
    +22.50 (+0.13%)
     

  • VOLATILITY

    16.73
    -0.21 (-1.24%)
     

  • FTSE

    8,051.73
    +27.86 (+0.35%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6841
    -0.0009 (-0.13%)
     

Aphria Inc. (APHA) Outpaces Stock Market Gains: What You Should Know

Zacks Equity Research

In the latest trading session, Aphria Inc. (APHA) closed at $6.87, marking a +1.18% move from the previous day. This move outpaced the S&P 500's daily gain of 0.09%. Meanwhile, the Dow gained 0.09%, and the Nasdaq, a tech-heavy index, added 0.62%.

Heading into today, shares of the company had lost 2.02% over the past month, lagging the Medical sector's gain of 3.37% and the S&P 500's gain of 2.08% in that time.

APHA will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.05, down 66.67% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $73.60 million, up 686.32% from the year-ago period.

Investors should also note any recent changes to analyst estimates for APHA. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

ADVERTISEMENT

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 114.29% lower. APHA currently has a Zacks Rank of #3 (Hold).

The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 111, which puts it in the top 44% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Aphria Inc. (APHA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research